Table 3. Molecular characterization of... | American Society of Hematology

Table 3.

Molecular characterization of 20 highly stable, untreated CLL patients

	IgV_H
Patient	IgV_H family	IgV_H gene	% mutation, FR1-FR3^*	% mutation, CDR1-FR3†	BCL-6 mutations, %	p53 mutations
1	V_H2	S12-7	4.68	4.31	0	0
2	V_H2	S12-6	8.00	7.62	0.27	0
3	V_H3	3-72/DP-29	3.34	3.83	0	0
4	V_H3	3-72/DP-29	4.98	5.69	0.07	0
5	V_H3	3-72/DP-29	3.61	4.26	0.14	0
6	V_H4	4-39/DP-79	7.05	9.13	0.27	0
7	V_H3	3-74/DP-53	11.5	11.2	0.14	0
8	V_H2	2-05/VII-5	6.04	7.69	0.07	0
9	V_H1	1-02/DP-75	6.10	6.83	0	0
10	V_H2	S12-4	3.65	3.32	0.07	0
11	V_H3	LSG12.1	13.4	13.9	0.47	0
12	V_H4	4-34/4d76	7.72	9.23	0.20	0
13	V_H1	1-02/DP-75	8.44	11.2	0	0
14	V_H4	4-30.1/DP-65	4.68	4.78	0.07	0
15	V_H5	5-51/DP-73	1.35	1.46	0	0
16	V_H3	3-23/DP-47	10.7	12.0	0.07	0
17	V_H4	4-34/DP-63	7.51	7.88	0	0
18	V_H1	1-18/DP-14	4.10	2.96	0	0
19	V_H3	3-48/DP-51	10.8	14.1	0.27	0
20	V_H4	4-39/DP-79	6.82	7.80	0	0

	IgV_H
Patient	IgV_H family	IgV_H gene	% mutation, FR1-FR3^*	% mutation, CDR1-FR3†	BCL-6 mutations, %	p53 mutations
1	V_H2	S12-7	4.68	4.31	0	0
2	V_H2	S12-6	8.00	7.62	0.27	0
3	V_H3	3-72/DP-29	3.34	3.83	0	0
4	V_H3	3-72/DP-29	4.98	5.69	0.07	0
5	V_H3	3-72/DP-29	3.61	4.26	0.14	0
6	V_H4	4-39/DP-79	7.05	9.13	0.27	0
7	V_H3	3-74/DP-53	11.5	11.2	0.14	0
8	V_H2	2-05/VII-5	6.04	7.69	0.07	0
9	V_H1	1-02/DP-75	6.10	6.83	0	0
10	V_H2	S12-4	3.65	3.32	0.07	0
11	V_H3	LSG12.1	13.4	13.9	0.47	0
12	V_H4	4-34/4d76	7.72	9.23	0.20	0
13	V_H1	1-02/DP-75	8.44	11.2	0	0
14	V_H4	4-30.1/DP-65	4.68	4.78	0.07	0
15	V_H5	5-51/DP-73	1.35	1.46	0	0
16	V_H3	3-23/DP-47	10.7	12.0	0.07	0
17	V_H4	4-34/DP-63	7.51	7.88	0	0
18	V_H1	1-18/DP-14	4.10	2.96	0	0
19	V_H3	3-48/DP-51	10.8	14.1	0.27	0
20	V_H4	4-39/DP-79	6.82	7.80	0	0

Mutations were calculated from the 5′ end of FR1 to the 3′ end of FR3

Mutations were calculated from the 5′ end of CDR1 to the 3′ end of FR3